Strategic partnerships Leverage DHCG’s recent and ongoing partnerships and MOUs with Altruist Biologics, KunTuo, and Porton Advanced to position as a facilitator for joint ventures and co-development deals, especially in China and global manufacturing collaborations.

Global expansion Capitalize on the acquisition of CJ PARTNERS to strengthen cross-border regulatory and market access capabilities, bridging Western and Eastern developers with regulators and investors to accelerate global program progression.

Integrated ecosystem Promote the expanding DHCG ecosystem through past acquisitions (BioTechLogic, Converge Consulting, CJ PARTNERS) as a one-stop solution for CGT strategy, manufacturing, regulatory, and market access services to attract larger biopharma clients seeking integrated support.

Expanded service demand Client requests span manufacturing, process development, regulatory support, quality systems, and market research; target high-value bio/pharma and ATMP clients needing end-to-end consulting, especially for CGT manufacturing scale-up and comparability studies.

Health of the business Revenue range of 25M–50M with 51–200 employees suggests room for upsell into larger engagements and multi-project programs; propose tiered service packages, capacity planning services, and ongoing advisory programs to increase annual contract value.